AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

1. (Original) A 7-substituted tetracycline compound of the formula:



(I)

wherein:

R^4 and $R^{4'}$ are each alkyl;

R^5 is hydrogen, hydroxyl, or a prodrug moiety;

R^6 and $R^{6'}$ are each independently hydrogen, hydroxyl, alkyl, or taken together, alkenyl;

R^7 is an N-substituted phenyl; and pharmaceutically acceptable salts thereof, and pharmaceutically acceptable salts thereof.

2. (Original) The compound of claim 1, wherein R^5, R^6 and $R^{6'}$ are each hydrogen and R^4 and $R^{4'}$ are each methyl.

3. (Original) The compound of claim 1, wherein R^7 is 2-N-substituted phenyl.

4. (Original) The compound of claim 3, wherein said 2-N-substituted phenyl is substituted with a nitro group.

5. (Original) The compound of claim 4, wherein said compound is 7-(2-nitrophenyl) sancycline.

6. (Original) The compound of claim 3, wherein said 2-N-substituted phenyl is 2-amino substituted.

7. (Currently Amended) The compound of claim ~~5~~ 6, wherein said 2-amino substituent is dialkylamino.

8. (Original) The compound of claim 3, wherein said compound is selected from the group consisting of 7-(2-aminophenyl) sancycline, 7-(2-nitrophenyl) sancycline, 7-(2-N,N,-dimethylaminophenyl) sancycline, 7-(2-N,N,-diethylaminophenyl) sancycline, 7-(2-N,N,-dipropylaminophenyl) sancycline, and 7-(2-N,N,-dibutylaminophenyl) sancycline.

9. (Original) The compound of claim 7, wherein said dialkyl amino group is dimethylamino.

10. (Currently Amended) The compound of claim 9, wherein said compound is 7-([[4]]2-N,N,-dimethylaminophenyl) sancycline.

11. (Original) The compound of claim 1, wherein R^7 is 3-N-substituted phenyl.

12. (Currently Amended) The compound of claim ~~10~~ 11, wherein said 3-N-substituted phenyl is substituted with a nitro group.

13. (Original) The compound of claim 12, wherein said compound is 7-(3-nitrophenyl) sancycline.

14. (Original) The compound of claim 11, wherein said 3-N-substituted phenyl is 3-amino substituted.

15. (Original) The compound of claim 14, wherein said 3-amino substituent is dialkylamino.

16. (Currently Amended) The ~~method~~ compound of claim 14, wherein said compound is selected from the group consisting of 7-(3-aminophenyl) sancycline, 7-(3-N,N,-dimethylaminophenyl) sancycline, 7-(3-N,N,-diethylaminophenyl) sancycline, 7-(3-N,N,-dipropylaminophenyl) sancycline, and 7-(3-N,N,-dibutylaminophenyl) sancycline.

17. (Original) The compound of claim 15, wherein said dialkyl amino group is dimethylamino.

18. (Currently Amended) The compound of claim 17, wherein said compound is 7-([[4]]3-N,N,-dimethylaminophenyl) sancycline.

19. (Original) The compound of claim 1, wherein R^7 is 4-N-substituted phenyl.

20. (Original) The compound of claim 19, wherein said 4-N-substituted phenyl is substituted with a nitro group.

21. (Original) The compound of claim 20, wherein said compound is 7-(4-nitrophenyl) sancycline.

22. (Original) The compound of claim 19, wherein said 4-substituted phenyl is 4-amino substituted.

23. (Currently Amended) The compound of claim 22, wherein said 4-amino substituent is dialkylamino.

24. (Currently Amended) The ~~method~~ compound of claim 23, wherein said compound is ~~7-(4-aminophenyl) sancycline~~, 7-(4-N,N,-diethylaminophenyl) sancycline, 7-(4-N,N,-dipropylaminophenyl) sancycline, or 7-(4-N,N,-dibutylaminophenyl) sancycline.

25. (Currently Amended) The compound of claim 23, wherein said dialkyl amino group is dimethylamino.

26. (Original) The compound of claim 25, wherein said compound is 7-(4-N,N,-dimethylaminophenyl) sancycline.

27. (Original) A method for treating a tetracycline responsive state in a mammal, comprising administering to said mammal a 7-substituted tetracycline compound of formula (I):



(I)

wherein:

R^4 and $R^{4'}$ are each alkyl;

R^5 is hydrogen, hydroxyl, or a prodrug moiety;

R^6 and $R^{6'}$ are each independently hydrogen, hydroxyl, alkyl, or taken together, alkenyl;

R^7 is an N-substituted phenyl; and pharmaceutically acceptable salts thereof, such that the tetracycline responsive state is treated.

28. (Original) The method of claim 27, wherein R^5, R^6 and $R^{6'}$ are each hydrogen and R^4 and $R^{4'}$ are each methyl.

29. (Original) The method of claim 27, wherein R^7 is 2-N-substituted phenyl.

30. (Original) The method of claim 29, wherein said 2-N-substituted phenyl is substituted with a nitro group.

31. (Original) The method of claim 29, wherein said 2-N-substituted phenyl is 2-amino substituted.

32. (Original) The method of claim 29, wherein said compound is selected from the group consisting of 7-(2-aminophenyl) sancycline, 7-(2-nitrophenyl) sancycline, 7-(2-N,N,-dimethylaminophenyl) sancycline, 7-(2-N,N,-diethylaminophenyl) sancycline, 7-(2-N,N,-dipropylaminophenyl) sancycline, and 7-(2-N,N,-dibutylaminophenyl) sancycline.

33. (Original) The method of claim 27, wherein R^7 is 3-N-substituted phenyl.

34. (Original) The method of claim 33, wherein said 3-N-substituted phenyl is substituted with a nitro group.

35. (Original) The method of claim 33, wherein said 3-N-substituted phenyl is 3-amino substituted.

36. (Original) The method of claim 33, wherein said compound is selected from the group consisting of 7-(3-aminophenyl) sancycline, 7-(3-nitrophenyl) sancycline, 7-(3-N,N,-dimethylaminophenyl) sancycline, 7-(3-N,N,-diethylaminophenyl) sancycline, 7-(3-N,N,-dipropylaminophenyl) sancycline, and 7-(3-N,N,-dibutylaminophenyl) sancycline.

37. (Original) The method of claim 27, wherein R^7 is 4-N-substituted phenyl.

38. (Original) The method of claim 37, wherein said 4-N-substituted phenyl is substituted with a nitro group.

39. (Original) The method of claim 37, wherein said 4-substituted phenyl is 4-amino substituted.

40. (Currently Amended) The method of claim ~~39~~ 37, wherein said compound is 7-(4-aminophenyl) sancycline, 7-(4-nitrophenyl) sancycline, 7-(4-N,N,-dimethylaminophenyl) sancycline, 7-(4-N,N,-diethylaminophenyl) sancycline, 7-(4-N,N,-dipropylaminophenyl) sancycline, or 7-(4-N,N,-dibutylaminophenyl) sancycline.

41. (Original) The method of claim 27, wherein said tetracycline responsive state is a bacterial infection.

42. (Original) The method of claim 41, wherein said bacterial infection is associated with *E. coli.*

43. (Original) The method of claim 41, wherein said bacterial infection is associated with *S. aureus*.

44. (Original) The method of claim 41, wherein said bacterial infection is associated with *E. faecalis.*

45. (Original) The method of claim 41, wherein said bacterial infection is resistant to other tetracycline antibiotics.

46. (Original) The method of claim 27, wherein said compound is administered with a pharmaceutically acceptable carrier.

47. (Original) A pharmaceutical composition comprising a therapeutically effective amount of a compound of claim 1 and a pharmaceutically acceptable carrier.

48. (Original) The pharmaceutical composition of claim 47, wherein said compound is selected from the group consisting of 7-(2-aminophenyl) sancycline, 7-(2-nitrophenyl) sancycline, 7-(2-N,N,-dimethylaminophenyl) sancycline, 7-(2-N,N,-diethylaminophenyl) sancycline, 7-(2-N,N,-dipropylaminophenyl) sancycline, 7-(2-N,N,-

dibutylaminophenyl) sancycline, 7-(3-aminophenyl) sancycline, 7-(3-nitrophenyl) sancycline, 7-(3-N,N,-dimethylaminophenyl) sancycline, 7-(3-N,N,-diethylaminophenyl) sancycline, 7-(3-N,N,-dipropylaminophenyl) sancycline, 7-(3-N,N,-dibutylaminophenyl) sancycline, 7-(4-aminophenyl) sancycline, 7-(4-nitrophenyl) sancycline, 7-(4-N,N,-dimethylaminophenyl) sancycline, 7-(4-N,N,-diethylaminophenyl) sancycline, 7-(4-N,N,-dipropylaminophenyl) sancycline, and 7-(4-N,N,-dibutylaminophenyl) sancycline.

49. (New) The compound of claim 22, wherein said compound is 7-(4-aminophenyl)sancycline.